← Compound index
COMPOUND RECORD / TACTIVIN

TactivinТактивин

A mixture of peptides extracted from thymus tissue, also called Taktivin, studied in immune-system research.

Source linked

What the studies found

Comparison in people · 1996

Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.

Reported survival time
40 versus 24 monthsT-activin + surgery versus surgery aloneReported follow-upNot statistically significant
Disease-free interval
17.5 versus 13 monthsSame comparison; described as similar
Lymphoproliferative response
Increase in 4 of 5 treated patients with progressionBiological response did not correspond to clinical benefit

In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.

Study notes · methods, sources and limitations

Participants or model 17 melanoma patients: 8 surgery plus T-activin; 9 surgery-only controls

Design T-activin + surgery 8; surgery alone 9; early-stage melanoma; follow-up February 1991–August 1995.

Participants
8 treated; 9 controls

Important limitations

  • Very small adjunctive comparison; random allocation and blinding are not established by the abstract. Immune-marker changes did not correlate with clinical course and should not be presented as proven cancer benefit.
  • The survival-time summary is not labeled as a median in the abstract. The small, non-randomized study does not establish a cancer-survival benefit.

Neoplasma. 43(4):245–252 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2011

Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison

Study of multiple preparations

Clinical improvement
73.7% versus 57.1%Imunofan-based care versus the pooled thymic-peptide group. Denominators conflict in the paper.
Fewer, shorter or no recurrences
36.8% versus 28.6%Composite reported in Table 2.
Immunogram normalization
85.7% versus 84.3%Table 2. No formal between-group test given for these percentages.

The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.

More reported outcomes
Temperature normalization
21% versus 14.3%
Lower antiviral or antibacterial antibody titres
31.6% versus 14.3%
CD3 lymphocytes
53.34 ± 1.55% to 65.8 ± 1.70%Within the Imunofan group.Reported p < 0.05
CD4 lymphocytes
31.36 ± 1.29% to 36.95 ± 1.40%Within the Imunofan group.Reported p < 0.05
Spontaneous IFN-γ
23.8 ± 2.47 to 42.13 ± 7.75 pg/mLWithin the Imunofan group.Reported p < 0.05
Stimulated IFN-γ
1,669.7 ± 123.1 to 2,170.6 ± 89.8 pg/mLWithin the Imunofan group.Reported p < 0.05
Study notes · methods, sources and limitations

Participants or model Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).

Design The methods list 35 patients per group but also give 29 women and 8 men in the Imunofan arm. Assignment followed order of presentation. Both groups received individualized care. The comparator pooled Thymalin, Thymogen and Tactivin. Lymphocyte markers and IFN-γ were assessed before and after treatment.

Important limitations

  • The comparison group pooled Thymalin, Thymogen and Tactivin. The paper gives no drug-specific subgroup outcomes, so the rates cannot establish a difference versus any one preparation. The groups were assigned in order of presentation and differed in average age. Concurrent antimicrobial and immune-active treatment varied by clinical presentation. The Imunofan denominator conflicts within the methods, and Table 2 supplies percentages without event counts or a separate significance test. No systematic adverse-event results were reported.
  • The Table 2 percentages are reproduced as published. The paper gives conflicting group sizes and no event counts, and the groups received different care. The IFN-γ and lymphocyte figures are within-group changes.

Public Health of the Far East. 2011;3(49):38–41. · Original journal article

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Observational study · 1994

Clinico-immunologic effect of tactivin in chronic myeloid leukemia

Infectious complications
1.77-fold reduction reportedRaw events and comparator denominator not supplied

Adjunctive Tactivin was reported to improve cellular immunity and reduce infectious complications 1.77-fold. The abstract gives no raw infection counts or comparison-arm sizes.

Study notes · methods, sources and limitations

Participants or model 35 advanced chronic-myeloid-leukemia patients underwent immune assessment around myelosan chemotherapy.

Design 35 advanced chronic-myeloid-leukemia patients underwent immune assessment around myelosan chemotherapy.

Assessed population
35 patients with advanced CML

Important limitations

  • A historical adjunctive report, not evidence of leukemia control or survival benefit. The fold claim cannot be converted into absolute risk without denominators.

Gematologiia i transfuziologiia 1994 · Journal publication

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Tactivin

Names in this research collection

Taktivin

Identity / background source ↗

Research background

Thymus-derived polypeptide preparation studied as an immune adjunct and in animal learning models. Clinical findings include a reported infection reduction in leukemia and a neutral melanoma comparison.

Autoimmune research: disease-specific findings, immune effects and open questions ↗

More study findings

Animal research · 2015

Thymus Polypeptide Preparation Tactivin Restores Learning and Memory in Thymectomied Rats

Active-avoidance learning
Restored with Tactivin; splenic polypeptides ineffective

Tactivin restored learning after thymectomy in young rats, whereas splenic polypeptides did not. The reported treatment was 0.5 mg/kg for one month.

Study notes · methods, sources and limitations

Participants or model Rats thymectomized at three weeks of age; active-avoidance learning assay.

Design Rats thymectomized at three weeks of age; active-avoidance learning assay.

Reported regimen
0.5 mg/kg for 1 month after surgery

Important limitations

  • An animal thymectomy model; no effect size, group counts or human cognitive outcomes are supplied in the indexed abstract.

Bulletin of experimental biology and medicine 2015 · Journal publication

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2001

Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma

Study of multiple preparations

Radiation complications and immune measures
Improvement reported with both agents; Imunofan described as more effective; numerical rates absent

Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.

Study notes · methods, sources and limitations

Participants or model Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.

Design Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.

Important limitations

  • Group sizes, allocation details, complication counts and cancer-survival endpoints are unavailable. A 2004 Tver abstract by Gladkova and colleagues includes Venediktova as a coauthor. Participant overlap is unresolved.

Eksperimental'naia i klinicheskaia farmakologiia 2001 · Journal publication

Original source or citation ↗

Study results and tables ↗

Research updates ↗

RELATED COMBINATION RESEARCH / 8 NOVEMBER 2026

T-activin in an alternative-treatment patent

The 1991 psoriasis patent selected T-activin, Thymalin or Dalargin as alternatives alongside photochemotherapy. Its selected case results do not demonstrate an isolated peptide effect or a combined Thymalin–Dalargin regimen.

Study methods, measured results and source limits ↗

Compound class
Archival preparation lead
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Historical adjunctive clinical comparisons and observational reports

Study methods

Source-specific clinical abstracts and rat thymectomy experiment

Independent replication

Related reports are not automatically independent evidence

Source access

Primary-publication records linked; full-text versus abstract review shown per source

Safety evidence

Clinical safety, product equivalence and interactions not established by this collection

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

Group assignment, comparators, planned outcomes, effect estimates, adverse events and possible participant overlap are key limits to interpreting the studies.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

1991 · SU1674849A1 · Immune-profile-directed peptide selection with psoriasis photochemotherapyUse · Dalargin case B cells 10%→20%; Thymalin case 32%→13%; T-activin case 28.6%→14%

Reported findings

The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.

Alternative-treatment examples
Dalargin case B cells 10%→20%; Thymalin case 32%→13%; T-activin case 28.6%→14%One selected patient per peptide, with photochemotherapy; changes are not comparative treatment effects
Dalargin case: immune measures
T-suppressor index 9%→25%; T-helper index 71%→55%Example 2; B cells 10%→20%; historical subset methods are not modern Treg measurements
All reported results, comparisons and limitations →

Use. Selects Dalargin, Thymalin or T-activin as alternatives according to historical lymphocyte profiles, alongside photochemotherapy. Not a claim to simultaneous Thymalin–Dalargin administration.

Selected case reports with photochemotherapy and historical immune assays; no controlled pair trial or isolated peptide effect. Russian dose/frequency statements are distinguished from mistranslated English text.

Publication
SU1674849A1 ↗ · 1991-09-07
Earliest priority / filing
1989-03-20 / 1989-03-20
Original applicant / assignee
Irkutsk State Medical Institute
Indexed status
Current legal status not established from this indexed record; official register not reviewed · checked 2026-11-08
Patent family
21434935 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Способ лечения псориаза

Inventors: I. O. Malova; R. G. Skvortsova; N. P. Kuznetsova.

SU1674849A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Comparison in people · 2011

Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison

The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.

Study notes and original source
2011Human comparative studyFull text available

Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison

· Original journal article

Y. V. Redkin, T. M. Lyuboshenko · Public Health of the Far East. 2011;3(49):38–41.

The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.

Results and tables

Reported findings and study design

The methods list 35 patients per group but also give 29 women and 8 men in the Imunofan arm. Assignment followed order of presentation. Both groups received individualized care. The comparator pooled Thymalin, Thymogen and Tactivin. Lymphocyte markers and IFN-γ were assessed before and after treatment.

Population or model Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).

Dose, route and schedule

The paper reports 1 mL intramuscularly every three days for 10–15 injections. Its printed concentration differs from the product labeling, so the amount of active peptide per injection cannot be confirmed from this report.

Protocol source ↗ · Original methods, p. 40

Results · Original journal issue, Table 2 and accompanying text
MeasureResultComparison, timing and statistics
Clinical improvement73.7% versus 57.1%Imunofan-based care versus the pooled thymic-peptide group. Denominators conflict in the paper.
Fewer, shorter or no recurrences36.8% versus 28.6%Composite reported in Table 2.
Immunogram normalization85.7% versus 84.3%Table 2. No formal between-group test given for these percentages.
Temperature normalization21% versus 14.3%
Lower antiviral or antibacterial antibody titres31.6% versus 14.3%
CD3 lymphocytes53.34 ± 1.55% to 65.8 ± 1.70%Within the Imunofan group. · Reported p < 0.05
CD4 lymphocytes31.36 ± 1.29% to 36.95 ± 1.40%Within the Imunofan group. · Reported p < 0.05
Spontaneous IFN-γ23.8 ± 2.47 to 42.13 ± 7.75 pg/mLWithin the Imunofan group. · Reported p < 0.05
Stimulated IFN-γ1,669.7 ± 123.1 to 2,170.6 ± 89.8 pg/mLWithin the Imunofan group. · Reported p < 0.05

The Table 2 percentages are reproduced as published. The paper gives conflicting group sizes and no event counts, and the groups received different care. The IFN-γ and lymphocyte figures are within-group changes.

Source for these results ↗ · Reviewed 2026-11-10

Population / setting
Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).
Source reviewed
Original issue PDF, pp. 38–41, including both tables and the methods.
Study limitations
  • The comparison group pooled Thymalin, Thymogen and Tactivin. The paper gives no drug-specific subgroup outcomes, so the rates cannot establish a difference versus any one preparation.
  • The groups were assigned in order of presentation and differed in average age. Concurrent antimicrobial and immune-active treatment varied by clinical presentation.
  • The Imunofan denominator conflicts within the methods, and Table 2 supplies percentages without event counts or a separate significance test. No systematic adverse-event results were reported.

Reviewed 2026-11-10.

Read the source ↗

Experiment described in a patent · 1991

Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1

The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.

Study notes and original source
1991Patent / reported experimentsFull text available

Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

I. O. Malova, R. G. Skvortsova, N. P. Kuznetsova · SU1674849A1 · patent family 21434935

The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.

Results and tables

Reported patent results

Reported findings

The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.

Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.

Population or model Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.

Results · Original Russian patent text as indexed, three selected examples; scan and aggregate table not recovered
MeasureResultComparison, timing and statistics
Alternative-treatment examplesDalargin case B cells 10%→20%; Thymalin case 32%→13%; T-activin case 28.6%→14%One selected patient per peptide, with photochemotherapy; changes are not comparative treatment effects
Dalargin case: immune measuresT-suppressor index 9%→25%; T-helper index 71%→55%Example 2; B cells 10%→20%; historical subset methods are not modern Treg measurements
Thymalin case: immune measuresT-suppressor index 33%→30%; T-helper index 35%→57%Example 3; B cells 32%→13%
T-activin case: immune measuresT-suppressor index 40%→34%; T-helper index 31.4%→52%Example 1; B cells 28.6%→14%
Clinical course in selected casesDischarge reported on day 19 with Dalargin and day 21 with Thymalin or T-activinIndividual clinical descriptions; no matched control or causal days-saved estimate
Russian-text peptide schedulesDalargin 1 mg intramuscularly twice daily for 5 days; Thymalin 5 mg intramuscularly once daily for 4 days; or T-activin 50 µg subcutaneously daily for 5 daysAlternative historical treatments with photochemotherapy, not a combined or current prescribing regimen
Translation and extraction gapsEnglish abstract mistranslates T-activin as 50 mg; one Thymalin case mistranslates frequency as four times dailyRussian text and course totals specify 50 µg and once daily, respectively. Patent PDF and aggregate comparison table not recovered.
Three selected patent cases: before → after
Three selected patent cases: before → after
Historical immune measureDalargin, example 2Thymalin, example 3T-activin, example 1
B-lymphocytes (%)10→2032→1328.6→14
T-suppressor index (%)9→2533→3040→34
T-helper index (%)71→5535→5731.4→52

Case descriptions, not study-arm means; n=1 selected patient per preparation. Photochemotherapy was concurrent. Historical subset labels do not establish modern regulatory-T-cell phenotypes.

This patent supports an early hypothesis of immune-profile-dependent peptide selection, not Thymalin–Dalargin synergy. The before/after changes cannot isolate peptide effects from photochemotherapy, natural fluctuation or selection of favorable cases.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • Selected case reports with photochemotherapy and historical immune assays; no controlled pair trial or isolated peptide effect. Russian dose/frequency statements are distinguished from mistranslated English text.
  • This patent supports an early hypothesis of immune-profile-dependent peptide selection, not Thymalin–Dalargin synergy. The before/after changes cannot isolate peptide effects from photochemotherapy, natural fluctuation or selection of favorable cases.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 2015

Thymus Polypeptide Preparation Tactivin Restores Learning and Memory in Thymectomied Rats

Tactivin restored learning after thymectomy in young rats, whereas splenic polypeptides did not. The reported treatment was 0.5 mg/kg for one month.

Study notes and original source
2015Animal / experimentalEnglish abstract

Thymus Polypeptide Preparation Tactivin Restores Learning and Memory in Thymectomied Rats

Thymus-derived polypeptide preparation · Journal publication

Novoseletskaya AV, Kiseleva NM, Zimina IV, Bystrova OV, Belova OV, Inozemtsev AN, Arion VY, Sergienko VI · Bulletin of experimental biology and medicine 2015

Tactivin restored learning after thymectomy in young rats, whereas splenic polypeptides did not. The reported treatment was 0.5 mg/kg for one month.

Results and tables

Reported findings and study design

Tactivin restored learning after thymectomy in young rats, whereas splenic polypeptides did not. The reported treatment was 0.5 mg/kg for one month.

Rats thymectomized at three weeks of age; active-avoidance learning assay.

Population or model Rats thymectomized at three weeks of age; active-avoidance learning assay.

Results · Primary-publication indexed abstract
MeasureResultComparison, timing and statistics
Active-avoidance learningRestored with Tactivin; splenic polypeptides ineffective
Reported regimen0.5 mg/kg for 1 month after surgery

An animal thymectomy model; no effect size, group counts or human cognitive outcomes are supplied in the indexed abstract.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
Rats thymectomized at three weeks of age; active-avoidance learning assay.
Source reviewed
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
  • An animal thymectomy model; no effect size, group counts or human cognitive outcomes are supplied in the indexed abstract.

Reviewed 2026-11-01.

Read the source ↗

Observational study · 1994

Clinico-immunologic effect of tactivin in chronic myeloid leukemia

Adjunctive Tactivin was reported to improve cellular immunity and reduce infectious complications 1.77-fold. The abstract gives no raw infection counts or comparison-arm sizes.

Study notes and original source
1994Uncontrolled human reportEnglish abstract

Clinico-immunologic effect of tactivin in chronic myeloid leukemia

Thymus-derived polypeptide preparation · Journal publication

Abdulkadyrov KM, Guseva SA · Gematologiia i transfuziologiia 1994

Adjunctive Tactivin was reported to improve cellular immunity and reduce infectious complications 1.77-fold. The abstract gives no raw infection counts or comparison-arm sizes.

Results and tables

Reported findings and study design

Adjunctive Tactivin was reported to improve cellular immunity and reduce infectious complications 1.77-fold. The abstract gives no raw infection counts or comparison-arm sizes.

35 advanced chronic-myeloid-leukemia patients underwent immune assessment around myelosan chemotherapy.

Results · Primary-publication indexed abstract
MeasureResultComparison, timing and statistics
Infectious complications1.77-fold reduction reportedRaw events and comparator denominator not supplied
Assessed population35 patients with advanced CML

A historical adjunctive report, not evidence of leukemia control or survival benefit. The fold claim cannot be converted into absolute risk without denominators.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
35 advanced chronic-myeloid-leukemia patients underwent immune assessment around myelosan chemotherapy.
Source reviewed
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
  • A historical adjunctive report, not evidence of leukemia control or survival benefit. The fold claim cannot be converted into absolute risk without denominators.

Reviewed 2026-11-01.

Read the source ↗

Comparison in people · 2001

Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma

Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.

Study notes and original source
2001Human comparative studyEnglish abstract

Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma

Tactivin tissue extract and synthetic Imunofan as separate comparisons · Journal publication

Venediktova MG · Eksperimental'naia i klinicheskaia farmakologiia 2001

Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.

Results and tables

Reported findings and study design

Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.

Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.

Population or model Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.

Results · Primary-publication indexed abstract
MeasureResultComparison, timing and statistics
Radiation complications and immune measuresImprovement reported with both agents; Imunofan described as more effective; numerical rates absent

Group sizes, allocation details, complication counts and cancer-survival endpoints are unavailable. A 2004 Tver abstract by Gladkova and colleagues includes Venediktova as a coauthor. Participant overlap is unresolved.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
Source reviewed
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
  • Group sizes, allocation details, complication counts and cancer-survival endpoints are unavailable. A 2004 Tver abstract by Gladkova and colleagues includes Venediktova as a coauthor. Participant overlap is unresolved.

Reviewed 2026-11-01.

Read the source ↗

Comparison in people · 1996

Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.

In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.

Reported survival time · 40 versus 24 months · T-activin + surgery versus surgery alone · Reported follow-up · Not statistically significant

Study notes and original source
1996Human comparative studyEnglish abstract

Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.

T-activin thymus preparation

Format: Journal article · Reviewed: Indexed abstract reviewed

N. Stanojević-Bakić, D. Milosević, L. Vucković-Dekić, M. Sasić, L. Marković · Neoplasma. 43(4):245–252

In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.

Results and tables

Reported findings and study design

In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.

T-activin + surgery 8; surgery alone 9; early-stage melanoma; follow-up February 1991–August 1995.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Reported survival time40 versus 24 monthsT-activin + surgery versus surgery alone · Reported follow-up · Not statistically significant
Disease-free interval17.5 versus 13 monthsSame comparison; described as similar
Lymphoproliferative responseIncrease in 4 of 5 treated patients with progressionBiological response did not correspond to clinical benefit
Participants8 treated; 9 controls

The survival-time summary is not labeled as a median in the abstract. The small, non-randomized study does not establish a cancer-survival benefit.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
17 melanoma patients: 8 surgery plus T-activin; 9 surgery-only controls
Source reviewed
Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Study limitations
  • Very small adjunctive comparison; random allocation and blinding are not established by the abstract.
  • Immune-marker changes did not correlate with clinical course and should not be presented as proven cancer benefit.

Reviewed 2026-11-01.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗